Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for spirometric and clinical outcomes in COPD with pulmonary hypertension
IRCT20251127068134N1Phase 2Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of empagliflozin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Spirometry parameters, Activity class and 4 more. Started Jan 2026; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20251127068134N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251127068134N1.